Legal advisor to the management of Julius Clinical on sale to Ampersand Capital Partners

Acted as legal advisor to the management of Julius Clinical Research in connection with the sale to Ampersand Capital Partners.

Julius Clinical is a contract research organization active in clinical research. The investment by Ampersand Capital Partners was intended to support further growth and international expansion, including in Europe and North America. Dealmaker lists the transaction as “Ampersand Capital Partners acquires Julius Clinical”, with a EUR 25–50 million transaction value category and a transaction date of 23 November 2023.

The legal work focused on the management position in the transaction, sale documentation, management participation and arrangements with the new investor. In private equity transactions involving management, the sale, reinvestment, governance and future management position need to be carefully aligned.

Need legal advice on a private equity transaction or management participation?

For questions about management participation, reinvestment, shareholder documentation or private equity transactions, please contact dirk.dewaard@viottalaw.com.

Deal highlights

Transaction type – Sale / private equity transaction / management participation

Client – Management of Julius Clinical Research

Buyer – Ampersand Capital Partners

Sector – Life sciences / clinical research / CRO

Role – Legal advisor to management

Legal work – Transaction documentation, management position, reinvestment, governance and private equity arrangements

Links
Dealmaker — Ampersand Capital Partners acquires Julius Clinical
Julius Clinical press release
PR Newswire

Related expertise

Private equity
Corporate / M&A
Shareholders agreement
Investment agreement
Commercial contracts

Involved lawyers.

If you need a legal opinion under Dutch law, please do not hesitate to contact us via
info@viottalaw.com or +31 20 248 06 00.

By VIOTTA.

Recent cases.

By VIOTTA.

More articles.

16 / 09 2026

Legal Due Diligence Readiness for Dutch Startups

A Dutch startup should enter investor due diligence with a reconciled cap table, complete corporate records, a clear IP chain and documented equity arrangements. This article explains which legal issues should be addressed before diligence starts and how Dutch counsel can prepare the company for an efficient financing process.

READ ARTICLE
16 / 09 2026

Dutch Startup Share Options in 2027: Tax Reform, SARs and Investor Implications

The Netherlands is proposing a more favourable tax regime for employee share options at qualifying startups and scale-ups from 2027. For foreign investors and founders, the development also affects option pools, dilution, Dutch BV approvals, SAR structures, due diligence and exit treatment.

READ ARTICLE
15 / 09 2026

Structuring the Purchase Price in Dutch M&A: Value, Price and Exit

Economic value, agreed purchase price and the exit proceeds ultimately received by shareholders are not the same. This article explains how purchase prices in Dutch M&A are structured through locked box and completion accounts mechanisms, vendor loans, deferred consideration, earn-outs and staged equity transfers, and how liquidation preferences and exit waterfalls affect founders and investors in VC-backed Dutch companies.

READ ARTICLE
09 / 09 2026

Valuation Gaps in Dutch M&A

Valuation gaps in Dutch M&A are increasingly solved through transaction structure rather than headline price alone. This article explains how buyers and sellers use earn-outs, vendor loans, deferred consideration, rollover equity, locked box, completion accounts, due diligence and LOI drafting to bridge uncertainty in a selective Dutch mid-market.

READ ARTICLE
31 / 08 2026

Can a VC Investor Block a Dividend Distribution in a Dutch BV?

A VC investor can receive a veto right over dividend distributions in a Dutch BV, but that right must be drafted and exercised within the Dutch governance framework. This article explains investor consent rights, Dutch reasonableness and fairness, the distribution test, the role of the board and the company’s interest.

READ ARTICLE
31 / 08 2026

Exiting a Dutch PE Investment

Exiting a Dutch PE investment can involve a trade sale, secondary buy-out, recapitalization, continuation vehicle, management buy-out or IPO. This article explains exit routes, management rollover, vendor due diligence, W&I insurance, drag-along, governance, disclosure and Dutch notarial closing mechanics.

READ ARTICLE